IGFBP5: A Promising Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Target Name: IGFBP5

NCBI ID: G3488

IGFBP5

IGFBP5: A Promising Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and chronic obstructive pulmonary disease (COPD), affect millions of people worldwide and cause significant morbidity and mortality. Chronic inflammation in these diseases can lead to various cellular and molecular changes in the body, including the production of pro-inflammatory cytokines and the activation of immune cells. The IGFBP5 gene, which encodes a protein known as IGFBP5, has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases.

The IGFBP5 gene: structure and function

The IGFBP5 gene is located on chromosome 1p36 and encodes a 21-kDa protein. The protein is composed of an N-terminus of 15 amino acids, a catalytic domain of 6 amino acids, and a C-terminus of 92 amino acids. The IGFBP5 protein plays a critical role in the regulation of insulin sensitivity and inflammation in the body.

Expression and regulation of IGFBP5

IGFBP5 is highly expressed in various tissues and organs, including liver, muscle, heart, kidney, and intestine. The protein is mainly expressed in the liver, where it is synthesized and degraded. The level of IGFBP5 expression is regulated by various factors, including insulin, obesity, and inflammation.

IGFBP5 is a key regulator of the inflammatory response

IGFBP5 has been shown to play a crucial role in the regulation of inflammatory responses in the body. The IGFBP5 protein has been shown to regulate the production of pro-inflammatory cytokines, such as TNF-浼?, IL-1, and IL-6, by suppressing the activity of the transcription factor, NF-kappa-B. IGFBP5 has also been shown to regulate the production of anti-inflammatory cytokines, such as IL-10, by activating the transcription factor, IRF-4.

IGFBP5 is involved in the development and progression of chronic diseases

Chronic diseases, such as rheumatoid arthritis, inflammatory bowel disease, and COPD, are characterized by chronic inflammation in the body. IGFBP5 has been shown to be involved in the development and progression of these diseases by promoting the production of pro-inflammatory cytokines and promoting the recruitment of immune cells to the site of inflammation.

Drug targeting IGFBP5

Several drugs have been developed targeting IGFBP5 in order to treat inflammatory diseases. One of the most promising drugs is metformin, which is a commonly used drug for the treatment of type 2 diabetes. Metformin has been shown to inhibit the activity of IGFBP5 and reduce the production of pro-inflammatory cytokines by suppressing the activity of the transcription factor, NF-kappa-B.

Another drug that has been shown to target IGFBP5 is onalizumab, a monoclonal antibody that targets the protein. Onalizumab has been shown to improve the symptoms of rheumatoid arthritis and improve the body's ability to fight off the infection in people with inflammatory bowel disease.

Conclusion

IGFBP5 is a protein that plays a critical role in the regulation of inflammatory responses in the body. The IGFBP5 gene has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases. Further research is needed to fully understand the role of IGFBP5 in the development and progression of inflammatory diseases and to develop safe and effective treatments.

Protein Name: Insulin Like Growth Factor Binding Protein 5

Functions: IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors

The "IGFBP5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGFBP5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets